PressFebruary 28, 2023 Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
PressFebruary 28, 2023 Enosis Therapeutics announces its response to Australian TGA decision, Plans to Present at SXSW 2023
PressFebruary 28, 2023 COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
PressFebruary 27, 2023 Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
PressFebruary 27, 2023 COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
PressFebruary 24, 2023 Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023
PressFebruary 23, 2023 FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302
PressFebruary 23, 2023 PSLY.com, Inc. Ei.Ventures, Inc. and Mycotopia Therapies Inc. Terminate Agreement and Plan of Merger
PressFebruary 21, 2023 Beckley Psytech receives FDA Investigational New Drug (IND) approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT (Mebufotenin)
PressFebruary 21, 2023 Irwin Naturals Closes Acquisition of Leading Kentucky Clinic adding $3 Million in Projected EBITDA, Company delivering on ambitious strategy to build largest global network of mental health clinics
PressFebruary 21, 2023 Field Trip Health & Wellness Ltd. to Release Fiscal 2023 Third Quarter Financial Results on Tuesday, February 28, 2023
PressFebruary 21, 2023 Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor
PressFebruary 17, 2023 Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
PressFebruary 17, 2023 FSD Pharma Inc. Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse
PressFebruary 17, 2023 SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
PressFebruary 17, 2023 Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity
PressFebruary 17, 2023 Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase
PressFebruary 17, 2023 Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
PressFebruary 17, 2023 Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
